Circulation Reports
Online ISSN : 2434-0790
Volume 5, Issue 7
Displaying 1-9 of 9 articles from this issue
Original Articles
Cardiac Rehabilitation
  • Satoshi Katano, Toshiyuki Yano, Ryo Numazawa, Ryohei Nagaoka, Kotaro Y ...
    Article type: ORIGINAL ARTICLE
    Subject area: Cardiac Rehabilitation
    2023 Volume 5 Issue 7 Pages 271-281
    Published: July 10, 2023
    Released on J-STAGE: July 10, 2023
    Advance online publication: June 20, 2023
    JOURNAL OPEN ACCESS FULL-TEXT HTML
    Supplementary material

    Background: A multidisciplinary team (MDT) approach is crucial for managing older patients with heart failure (HF). We investigated the impact on clinical outcomes of implementation of a conference sheet (CS) with an 8-component radar chart for visualizing and sharing patient information.

    Methods and Results: We enrolled 395 older inpatients with HF (median age 79 years [interquartile range 72–85 years]; 47% women) and divided them into 2 groups according to CS implementation: a non-CS group (before CS implementation; n=145) and a CS group (after CS implementation; n=250). The clinical characteristics of patients in the CS group were assessed using 8 scales (physical function, functional status, comorbidities, nutritional status, medication adherence, cognitive function, HF knowledge level, and home care level). In-hospital outcomes (Short Physical Performance Battery, Barthel Index score, length of hospital stay, and hospital transfer rate) were significantly better in the CS than non-CS group. During the follow-up period, 112 patients experienced composite events (all-cause death or admission for HF). Inverse probabilities of treatment-weighted Cox proportional hazard analyses demonstrated a 39% reduction in risk of composite events in the CS group (adjusted hazard ratio 0.65; 95% confidence interval 0.43–0.97).

    Conclusions: Radar chart-based information sharing among MDT members is associated with superior in-hospital clinical outcomes and a favorable prognosis.

Cardiovascular Intervention
  • Yasuhiro Nakano, Tetsuya Matoba, Mitsutaka Yamamoto, Shunsuke Katsuki, ...
    Article type: ORIGINAL ARTICLE
    Subject area: Cardiovascular Intervention
    2023 Volume 5 Issue 7 Pages 282-288
    Published: July 10, 2023
    Released on J-STAGE: July 10, 2023
    Advance online publication: June 06, 2023
    JOURNAL OPEN ACCESS FULL-TEXT HTML
    Supplementary material

    Background: Recent revisions of clinical guidelines by the Japanese Circulation Society, American Heart Association/American College of Cardiology, and European Society of Cardiology updated the management of antithrombotic strategies for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). However, the extent to which these guidelines have been implemented in real-world daily clinical practice is unclear.

    Methods and Results: We conducted surveys on the status of antithrombotic therapy for patients with AF undergoing PCI every 2 years from 2014 to 2022 in 14 cardiovascular centers in Japan. The primary use of drug-eluting stents increased from 10% in 2014 to 95–100% in 2018, and the use of direct oral anticoagulants increased from 15% in 2014 to 100% in 2018, in accordance with the revised practice guidelines. In patients with acute coronary syndrome, the duration of triple therapy within 1 month was approximately 10% until 2018, and increased to >70% from 2020. In patients with chronic coronary syndrome, the duration of triple therapy within 1 month was approximately 10% until 2016, and >75% from 2018. Since 2020, the most common timing of discontinuation of dual antiplatelet therapy to transition to anticoagulation monotherapy during the chronic phase of PCI has been 1 year after PCI.

    Conclusions: Japanese interventional cardiologists have updated their treatment strategies for patients with AF undergoing PCI according to revisions of clinical practice guidelines.

Heart Failure
  • Mariko Asase, Takuya Watanabe, Misa Takegami, Kunihiro Nishimura, Kazu ...
    Article type: ORIGINAL ARTICLE
    Subject area: Heart Failure
    2023 Volume 5 Issue 7 Pages 289-297
    Published: July 10, 2023
    Released on J-STAGE: July 10, 2023
    Advance online publication: June 09, 2023
    JOURNAL OPEN ACCESS FULL-TEXT HTML
    Supplementary material

    Background: Left ventricular assist device (LVAD) implantation improves survival and health-related quality of life (HRQoL) of patients with heart failure. However, the impact of LVADs or different LVAD-based therapeutic strategies on long-term HRQoL has not been investigated. We evaluated the long-term HRQoL of Japanese patients who were treated with different LVAD-based therapeutic strategies.

    Methods and Results: Patients whose data were recorded in the Japanese Registry for Mechanical Assisted Circulatory Support between January 2010 and December 2018 were divided into 3 groups: primary implantable LVAD (G-iLVAD; n=483), primary paracorporeal LVAD (n=33), and bridge-to-bridge from paracorporeal to implantable LVAD (n=65). HRQoL was evaluated using the EuroQoL 5-dimension 3-level (EQ-5D-3L) before and 3 and 12 months after LVAD implantation; the mean EQ-5D-3L visual analog scale (VAS) score in the G-iLVAD group at these time points was 47.4, 71.1, and 72.9, respectively (where scores of 0 and 100 indicate worst and best imaginable health state, respectively). Changes in the least squares means of the VAS scores at 3 and 12 months after implantation differed significantly among the 3 groups. Social function, disability, and physical and mental problems were significantly lower in the G-iLVAD than other groups.

    Conclusions: HRQoL improved significantly at 3 and 12 months after LVAD implantation in all groups. Physical function showed a stronger improvement than did social function, disability, and mental function.

Myocardial Disease
  • Masakazu Miyamoto, Kazufumi Nakamura, Koji Nakagawa, Nobuhiro Nishii, ...
    Article type: ORIGINAL ARTICLE
    Subject area: Myocardial Disease
    2023 Volume 5 Issue 7 Pages 298-305
    Published: July 10, 2023
    Released on J-STAGE: July 10, 2023
    Advance online publication: June 23, 2023
    JOURNAL OPEN ACCESS FULL-TEXT HTML

    Background: Various types of arrhythmia are observed in patients with cardiac amyloidosis, but the prevalence of arrhythmia has not been fully investigated. This study investigated the prevalence and treatment of arrhythmias in patients with cardiac amyloidosis before the introduction of new agents for amyloidosis, such as tafamidis.

    Methods and Results: Of 53 patients who were histologically diagnosed with cardiac amyloidosis at 10 centers in western Japan between 2009 and 2021, 43 who were diagnosed on the basis of immunohistochemical staining were evaluated in this study. Of these 43 patients, 13 had immunoglobulin light-chain (AL) amyloidosis and 30 had transthyretin (ATTR) amyloidosis; further, 27 had atrial tachyarrhythmia, 13 had ventricular tachyarrhythmia, and 17 had bradyarrhythmia. Atrial fibrillation (AF) was the most common arrhythmia in patients with cardiac amyloidosis (n=24; 55.8%), especially among those with ATTR amyloidosis (70.0% of ATTR vs. 23.1% of AL). Eleven (25.6%) patients were treated with a cardiac implantable device. All 3 patients with pacemakers were alive at the last follow-up (median 76.7 months; interquartile range [IQR] 4.8–146.4 months). Of the 8 patients who underwent AF ablation, there was no recurrence in 6 (75%) after a median of 39.3 months (IQR 19.8–59.3 months).

    Conclusions: The prevalence of various arrhythmias was high in patients with cardiac amyloidosis. AF occurred most frequently in patients with cardiac amyloidosis, especially among patients with ATTR.

Rapid Communications
  • Takahiro Suzuki, Atsushi Mizuno, Takuya Kishi, Jeffrey Rewley, Chisa M ...
    Article type: RAPID COMMUNICATION
    2023 Volume 5 Issue 7 Pages 306-310
    Published: July 10, 2023
    Released on J-STAGE: July 10, 2023
    Advance online publication: June 06, 2023
    JOURNAL OPEN ACCESS FULL-TEXT HTML

    Background: Previous research has investigated the effectiveness of the “Tweet the Meeting” campaign, but the relationship between tweet content and the number of retweets has not been fully evaluated.

    Methods and Results: We analyzed the number of tweets and retweets during the Japanese Circulation Society’s 2022 annual meeting. The ambassador group had significantly more session- and symposium-related tweets than the non-ambassador group (P<0.001), associated with the nubmer of retweets. Symposium-related tweets with figures generated more retweets than those without figures (mean [±SD] 3.47±3.31 vs. 2.48±1.94 retweets per tweet, respectively; P=0.001).

    Conclusions: The study revealed that official meeting-designated Twitter ambassadors disseminate more educational content than non-ambassadors, and generated more retweets.

Images in Cardiovascular Medicine
feedback
Top